Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance

International Journal of Cancer

Volumn 66, Issue 4, 1996, Pages 520-525

  Futscher, Bernard W ^a,b   Foley, Nils E ^a,b   Gleason Guzman, Mary C ^a,b   Meltzer, Paul S ^c   Sullivan, Daniel M ^d   Dalton, William S ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLYCOPROTEIN P; VERAPAMIL;

ARTICLE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

CELL NUCLEUS; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION; HUMANS; MULTIPLE MYELOMA; P-GLYCOPROTEIN; RNA, MESSENGER; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0029889369     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B     Document Type: Article

References (43)

1. BECK, W.T., Modulators of P-glycoprotein associated multidrug resistance. In: R.F. Ozols (ed.), Molecular and clinical advances in anticancer drug resistance, pp. 151-170 Kluwer, Philadelphia (1991).
2. BELLAMY, W.T., DALTON, W.S., KAILEY, J.M., GLEASON, M.C., MCCLOSKEY, T.M., DORR, R.T. and ALBERTS, D.S., Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res., 48, 6365-6370 (1988).
3. CAMPAIN, J.A., GOTTESMAN, M.M. and PASTAN, I., A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry, 33, 11327-11332 (1994).
4. CAMPAIN, J.A., PADMANABHAN, R., HWANG, J., GOTTESMAN, M.M. and PASTAN, I., Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. J. cell. Physiol., 155, 414-425 (1993).
5. CARMICHAEL, J., DEGRAFF, W.G., GAZDAR, A.F., MINNA, J.D. and MITCHELL, J.B., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936-942 (1987).
6. CHEN, Y.N., MICKLEY, L.A., SCHWARTZ, A.M., ACTON, E.M., HWANG, J. and FOJO, A.T., Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. biol. Chem., 265, 10073-10080 (1990).
7. CHIRGWIN, J.M., PRZYBYLA, A.E., MACDONALD, R.J. and RUTTER, W.J., Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18, 5294-5299 (1979).
8. COLE, S.P.C., SPARKS, K.E., FRASER, K., LOE, D.W., GRANT, C.E., WILSON, G.M. and DEELY, R.G., Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54, 5902-5910 (1994).
9. DALTON, W.S., Drug resistance modulation in the laboratory and the clinic. Semin. Oncol., 20, 64-69 (1993a).
10. DALTON, W.S., Overcoming the multidrug resistant phenotype. In: V. DeVita, Jr., S. Hellman and S.A. Rosenberg (eds.), Cancer:principles and practice of oncology, pp. 2655-2666 pp. 2655-2666. J.B. Lippincott, Philadelphia (1993b).
11. DALTON, W.S., GROGAN, T.M., MELTZER, P.S., SCHEPER, R.J., DURIE, B.G.M., TAYLOR, C.W., MILLER, T.P. and SALMON, S.E., Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. clin. Oncol., 7, 415-424 (1989a).
12. DALTON, W.S., GROGAN, T.M., RYBSKI, J.A., SCHEPER, R.J., RICHTER, L., KAILEY, J., BROXTERMAN, H., PINEDO, H.M. and SALMON, S.E., Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood, 73, 747-752 (1989b).
13. DALTON, W.S. and SIKIC, I.S., The multidrug-resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. J. N.I.H. Res., 6, 54-61 (1994).
14. DOYLE, L.A., ROSS, D.D., SRIDHARA, R., FOJO, AT., KAUFMANN, S.H. and LEE, E.J., Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. Brit. J. Cancer, 71, 52-58 (1995).
15. FORD, J.M. and HAIT, W.N., Pharmacologic circumvention of multidrug resistance. Cytotechnology, 12, 171-212 (1993).
16. FUCHS, B., OSTMEIER, H. and SUTER, L., P-glycoprotein expression in malignant melanoma. J. Cancer. Res. clin. Oncol., 117, 168-171 (1991).
17. FUTSCHER, B.W., ABBASZADEGAN, M.R., DOMANN, F. and DALTON, W.S., Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem. Pharmacol., 47, 1601-1606 (1994).
18. FUTSCHER, B.W., BLAKE, L.L., GERLACH, J.H., GROGAN, T.M. and DALTON, W.S., Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal. Biochem., 213, 414-421 (1993).
19. FUTSCHER, B.W., CAMPBELL, K. and DALTON, W.S., Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil. Cancer Res., 52, 5013-5017 (1992).
20. GERLACH, J.H., KARTNER, N., BELL, D.R. and LING, V., Multidrug resistance. Cancer Surv., 5, 25-46 (1986).
21. GOLDSTEIN, L.J. and 13 OTHERS, Expression of a multidrug resistance gene in human cancers. J. nat. Cancer Inst., 81, 116-124 (1989).
22. GROGAN, T.M., SPIER, C.M., SALMON, S.E., MATZNER, M., RYBSKI, J., WEINSTEIN, R.S., SCHEPER, R.J. and DALTON, W.S., P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, 81, 490-495 (1993).
23. HYAFIL, F., VERGELY, C., DU VIGNAUD, P. and GRAND-PERRET, T., In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 53, 4595-4602 (1993).
24. KAYE, S. and MERRY, S., Tumour cell resistance to anthracyclines - a review. Cancer Chemother. Pharmacol., 14, 96-103 (1985).
25. KRUH, G.D., CHAN, A., MYERS, K., GAUGHAN, K., MIKI, T. and AARONSON, S.A., Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res., 54, 1649-1652 (1994).
26. LEVINE, E.A., HOLZMAYER, T.A., RONINSON, I.B. and DAS GUPTA, T.K., MDR-1 expression in metastatic malignant melanoma. J. surg. Res., 54, 621-624 (1993).
27. LIST, A.F., SPIER, C., GREER, J., WOLFF, S., HUTTER, J., DORR, R., SALMON, S., BAIER, M. and DALTON, W., Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. clin. Oncol., 11, 1652-1660 (1993).
28. LONG, B.H., WANG, L., LORICO, A., WANG, R.C., BRATTAIN, M.G. and CASAZZA, A.M., Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res., 51, 5275-5283 (1991).
29. MARIE, J.P., BASTIE, J.N., COLOMA, F., FAUSSAT SUBERVILLE, A.M., DELMER, A., RIO, B., DELMAS-MARSALET, B., LEROUX, G., CASASSUS, P., BAUMELOU, E., CATALAN, J. and ZITTOUN, R., Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia, 7, 821-824 (1993).
30. MARIE, J.P., ZITTOUN, R. and SIKIC, B.I., Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 78, 586-592 (1991).
31. MILLER, T.P., CHASE, E.M., DALTON, W.S. and GROGAN, T.M., The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. In: F. Cabanillas and M.A. Rodriguez (eds.), Advances in lymphoma research, Kluwer, Norwell (In press) (1996).
32. MIRSKI, S.E., EVANS, C.D., ALMQUIST, K.C., SLOVAK, M.L. and COLE, S.P., Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res., 53, 4866-4873 (1993).
33. SAIJO, Y., SATOH, K., TOKUE, Y., KUMANO, N. and MOTOMIYA, M., Reduced topoisomerase II-mediated DNA cleavage in VP-16 resistant human leukemic cell line. Anticancer Res., 11, 445-448 (1991).
34. SCHADENDORF, D., HERFORDT, R. and CZARNETZKI, B.M., P-glycoprotein expression in primary and metastatic malignant melanoma. Brit. J. Dermatol., 132, 551-555 (1995).
35. SHUSTIK, C., DALTON, W. and GROS, P., P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol. Aspects Med., 16, 1-78 (1995).
36. SONNEVELD, P., DURIE, B.G., LOKHORST, H.M., MARIE, J.P., SOLBU, G., SUCIU, S., LOWENBERG, B. and NOOTER, K., Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, 340, 255-259 (1992).
37. SULLIVAN, D.M., GLISSON, B.S., HODGES, P.K., SMALLWOOD-KENTRO, S. and Ross, W.E., Proliferation dependence of topoisomerase II mediated drug action. Biochemistry, 25, 2248-2256 (1986).
38. SULLIVAN, D.M., LATHAM, M.D. and Ross, W.E., Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res., 47, 3973-3979 (1987).
39. TSURUO, T., IIDA, H., TSUKAGOSHI, S. and SAKURAI, Y., Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967-1972 (1981).
40. TWENTYMAN, P.R., WRIGHT, K.A. and FOX, N.E., Characterisation of a mouse tumour cell line with in vitro derived resistance to verapamil. Brit. J. Cancer, 61, 279-284 (1990).
41. WILSON, W.H., JAMIS-DOW, C., BRYANT, G., BALIS, P.M., KLECKER, R.W., BATES, S.E., STEINBERG, S.M., KOHLER, D.R. and WITTES, R.E., Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. clin. Oncol., 13, 1985-1994 (1995).
42. WOLVERTON, J.S., DANKS, M.K., SCHMIDT, C.A. and BECK, W.T., Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Cancer Res., 49, 2422-2426 (1989).
43. ZAMAN, G.J., VERSANTVOORT, C.H., SMIT, J.J., EIJDEMS, E.W., DE HAAS, M., SMITH, A.J., MULDER, N.H., DE VRIES, E.G., BAAS, F. and BORST, P., Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 53, 1747-1750 (1993).